

strategic support to senior managers in the determination of CDC's long term facilities needs; (3) directs the operations of FPMO staff involved in the planning, evaluation, design, construction, and management of facilities and acquisition of property; (4) processes data for management and control systems and develops reports and analyses; and (5) assists and advises senior CDC officials in the development, coordination, direction, and assessment of facilities and real property activities throughout CDC's facilities and operations, and assures consideration of facilities management implications in program decisions.

Delete the functional statement for the *Administrative and Program Services Activity (CAJ512)*, *Office of the Director (CAJ51)*, *Information Resources Management Office (CAJ5)* and insert the following:

(1) Provides assistance in formulating, developing, negotiating, managing, and administering various Information Resources Management Office and CDC-wide technology and service contracts; (2) maintains liaison with the staffs of other offices within the Office of the Chief Operating Officer and the administrative offices of the CIOs.

Delete the functional statement for the *Office of the Director (CA11)*, *Office of Health and Safety (CA1)* and insert the following:

(1) Provides leadership in developing and implementing the CDC Health and Safety Program (HSP); (2) coordinates the systematic inspection of facilities and critical review and evaluation of procedures and practices in relation to health and safety; provides recommendations for correction of inappropriate or unsafe conditions to appropriate management officials and monitors for compliance, taking appropriate action when necessary to ensure satisfactory remediation; (3) develops or ensures development of health and safety policies, rules, and recommendations, and critically reviews those from other CDC programs and locations; (4) serves as Executive Secretary of the Health and Safety Advisory Board and the Occupational Health and Safety Committee; (5) advises the Associate Director for Science and the Director, CDC, on health and safety related issues; (6) collects and analyzes health and safety data essential to the planning, implementation, and evaluation of the HSP; (7) takes the lead in developing and implementing safety awareness and health promotion programs for workers, supervisors, and management officials; (8) coordinates the review of plans and specifications of new construction and

renovations for biosafety and biocontainment requirements, for asbestos management, and for compliance with applicable standards and codes; (9) provides oversight for the Employee Health Services Clinic in Atlanta which provides a program of medical surveillance, preventative occupational medical services, and health promotion; ensures confidentiality of employee health records to the extent legally possible; (10) ensures that OHS provides expertise to local safety committees and collateral duty safety officers and provides assistance when requested; (11) provides for risk assessments not provided by the Branches; (12) provides consultation and direct support to workers, supervisors, and management officials on all aspects of the HSP; (13) makes available specialized training and/or training materials relative to health and safety; (14) ensures the regular critical review and updating of health and safety related publications including *Biosafety in Microbiological and Biomedical Laboratories*; (15) ensures the drafting, publication, and subsequent regular review and evaluation of a comprehensive Health and Safety Manual; (16) coordinates the development and maintenance of appropriate emergency plans and ensures that they are communicated to all concerned employees; (17) maintains liaison with appropriate Department and Agency officials on health and safety matters; (18) consults with individuals and organizations nationally and internationally on health and safety issues; (19) coordinates activities relative to the implementation of National Environmental Protection Agency (NEPA) for CDC activities and facilities.

Delete the functional statement for the *Resource Management Activity (CA113)*, *Office of the Director (CA11)*, *Office of Health and Safety (CA1)* and insert the following:

(1) Manages OHS centralized computer databases and internal applications; (2) develops and coordinates the implementation of security programs; (3) designs, implements, and evaluates OHS communication strategies including marketing messages, materials, and methods; (4) provides oversight for the Employee Health Services Clinic and the Worksite Health Promotion Programs for employees in the Atlanta area and for the Employee Assistance Program for employees based in Atlanta and remote locations.

Dated: March 2, 2004.

**William H. Gimson,**

*Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 04-5317 Filed 3-9-04; 8:45 am]

BILLING CODE 4160-18-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2002N-0204]

#### Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; "Bar Code Label Requirements for Human Drug Products and Biological Products"

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Bar Code Label Requirements for Human Drug Products and Biological Products" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

#### FOR FURTHER INFORMATION CONTACT:

JonnaLynn P. Capezzuto, Office of Management Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4659.

**SUPPLEMENTARY INFORMATION:** In the *Federal Register* of February 26, 2004 (69 FR 9120), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0537. The approval expires on February 28, 2007. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: March 5, 2004.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. 04-5406 Filed 3-9-04; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Allergenic Products Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Allergenic Products Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held via teleconference on April 2, 2004, from 1 p.m. to 3:40 p.m.

*Location:* Food and Drug Administration, Bldg. 29B, Conference Rooms A & B, 8800 Rockville Pike, Bethesda, MD. This meeting will be held by teleconference. The public is welcome to attend the meeting at the above location. A speaker phone will be provided at the specified location for public participation in this meeting.

*Contact Person:* William Freas or Jane Brown, Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512388. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On April 2, 2004, the committee will hear updates on the following topics: Personnel organization, research and regulatory work of the Laboratory of Immunobiochemistry in the Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics and an update on FDA activities relating to cockroach standardization. The committee will then discuss use of microarray technology in allergen standardization.

*Procedure:* On April 2, 2004, from 1 p.m. to 3:40 p.m., the meeting is open to the public. Interested persons may

present data, information, or views orally or in writing on issues pending before the committee. Written submissions may be made to the contact person by March 25, 2004. Oral presentations from the public will be scheduled between approximately 2:40 p.m. and 3:40 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 29, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact William Freas or Jane Brown at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: March 4, 2004.

**William K. Hubbard,**

*Associate Commissioner for Policy and Planning.*

[FR Doc. 04-5405 Filed 3-9-04; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information collection requests under review by the Office of Management and Budget, in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. chapter 35). To request a copy of the clearance requests submitted to OMB for

review, call the HRSA Reports Clearance Office on (301) 443-1129.

The following request has been submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995:

#### **Proposed Project: Data System for Organ Procurement and Transplantation Network and Associated Forms (OMB No. 0915-0157)—Revision**

Section 372 of the Public Health Service (PHS) Act requires that the Secretary, by contract, provide for the establishment and operation of an Organ Procurement and Transplantation Network (OPTN). The OPTN, among other responsibilities, operates and maintains a national waiting list of individuals requiring organ transplants, maintains a computerized system for matching donor organs with transplant candidates on the waiting list, and operates a 24-hour telephone service to facilitate matching organs with individuals included in the list.

Data for the OPTN data system are collected from transplant hospitals, organ procurement organizations, and tissue-typing laboratories. The information is used to match donor organs with recipients, to monitor compliance of member organizations with OPTN rules and requirements, and to report periodically on the clinical and scientific status of organ donation and transplantation in this country. Data are used in the development and revision of OPTN rules and requirements, operating procedures, and standards of quality for organ acquisition and preservation, some of which have provided the foundation for development of Federal regulations. The practical utility of the data collection is further enhanced by requirements that the OPTN data must be made available without restriction for use by OPTN members, the Scientific Registry of Transplant Recipients, the Department of Health and Human Services, and others for evaluation, research, patient information, and other important purposes.

Revisions in the 28 data collection forms are intended to clarify existing questions, to provide additional detail and categories to avoid confusion and be more inclusive, to remove obsolete data, and to comply with requests for more complete and precise data.

#### ESTIMATES OF ANNUALIZED HOUR BURDEN

Worksheet	Number of respondents	Responses per respondent	Total responses	Hours per response	Total burden hours
Deceased Donor Registration .....	59	173	10,207	0.3	3,062.10